Grail, Inc., a Menlo Park, California and Hong Kong-based healthcare company developing solutions to detect cancer early, raised $300m in financing.
The round was led by Ally Bridge Group, a global life science-focused investment group, with participation from Lifetech Scientific (HKSE:1302), through its joint venture with Ally Bridge, which was formed and announced in January 2018.
The company intends to use the funds to move towards commercialization of its first product in Hong Kong and advance its product development programs globally.
Led by Ken Drazan, President, Grail is a healthcare company working to detect cancer early using high-intensity sequencing, population-scale clinical studies, computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize other products for the early detection of cancer.
FinSMEs
22/05/2018